Technology enhances production yields and time and cost savings.
Viropro will use the National Research Council-Biotechnology Research Institute’s (NRC-BRI) inducible expression systems, under an agreement with them.

These expression systems are integrated into CHO cells, which are used by Viropro for its transfer of technology. They are designed to control and maximize the expression of proteins thus allowing high production yields, as well as time and cost savings, according to the company.

Viropro has also obtained a worldwide, exclusive licence for the production of the recombinant human interferon-&#946.

Previous articlePfizer and WHO Search for New Treatments against Tropical Diseases
Next articleAstraZeneca’s Stroke Drug Trial Failure Precipitates Stock Tumble